AVALO THERAPEUT. DL-,001 (C6K0.F)

9,86 -0,19 (-1,89%) Ab 08:14AM CEST. Markt geöffnet.

AVALO THERAPEUT. DL-,001

540 Gaither Road
Suite 400
Rockville, MD 20850
United States
410-522-8707
https://www.avalotx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 19

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Garry A. Neil M.D.	Chairman of the Board, President & CEO	440,39k	N/A	1954
Mr. Christopher Ryan Sullivan	CFO & Head of Investor relations	324,5k	N/A	1984
Dr. Solomon H. Snyder M.D.	Founder and Chairman of Scientific Advisory Board	N/A	N/A	1939
Dr. Barbara S. Slusher Ph.D.	Founder and Member of Scientific Advisory Board	N/A	N/A	1965
Dr. Lisa Hegg Ph.D.	Senior Vice President of Program Management, Corporate Infrastructure & Clinical Operations	N/A	N/A	N/A
Ms. Colleen Matkowski	Senior Vice President of Global Regulatory Affairs & Quality Assurance	N/A	N/A	N/A
Dr. Dino C. Miano Ph.D.	Senior Vice President of CMC & Technical Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Corporate Governance

AVALO THERAPEUT. DL-,001s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.